Investigating the Relationship between CD20-Rituximab Binding Force and Mechanical Properties of Lymphom B Cells using Atomic Force Microscopy

被引:0
作者
Li, Mi [1 ,4 ]
Liu, Lianqing [1 ,2 ]
Xi, Ning [1 ,3 ]
Wang, Yuechao [1 ]
Dong, Zaili [1 ]
Xiao, Xiubin [5 ]
Zhang, Weijing [5 ]
机构
[1] Chinese Acad Sci, Shenyang Inst Automat, State Key Lab Robot, Shenyang 110016, Peoples R China
[2] Grad Univ Chinese Acad Sci, Beijing, Peoples R China
[3] Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI USA
[4] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
[5] Affiliated Hosp Mil Med Acad Sci, Dept Lymphoma, Beijing, Peoples R China
来源
2012 INTERNATIONAL CONFERENCE ON MANIPULATION, MANUFACTURING AND MEASUREMENT ON THE NANOSCALE (3M-NANO) | 2012年
基金
中国国家自然科学基金;
关键词
atomic force microscopy; lymphoma; Rituximab;
D O I
暂无
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
The invention of atomic force microscopy (AFM) provides new technology for investigating the physiological activities at the single cell and single molecule levels. Lymphoma Raji cells were adsorbed onto the glass slides by coating the glass slides with poly-L-lysine. Rituximabs (anti-CD20 antibody) were linked onto the AFM tip by PEG linker and the CD20-Rituximab binding forces were measured on three lymphoma Raji cells. Then the mechanical properties of the Raji cells were dynamically measured after the Rituximab activation by obtaining force curves on the cell surface. The mechanical properties of lymphoma cells kept stable at the first 20-30 min, and then decreased markedly. Resides, as the CD20-Rituximab binding force increased, the mechanical properties decrease rate increased. The experimental results indicated that the Rituximab's effect is related to CD20-Rituximab binding force and can improve our understanding of Rituximab's variable efficacies in different patients.
引用
收藏
页码:50 / 53
页数:4
相关论文
共 20 条
[1]  
[Anonymous], 1988, Antibodies: A laboratory manual
[2]   Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection [J].
Beers, Stephen A. ;
French, Ruth R. ;
Chan, H. T. Claude ;
Lim, Sean H. ;
Jarrett, Timothy C. ;
Vidal, Regina Mora ;
Wijayaweera, Sahan S. ;
Dixon, Sandra V. ;
Kim, Hyungjin ;
Cox, Kerry L. ;
Kerr, Jonathan P. ;
Johnston, David A. ;
Johnson, Peter W. M. ;
Verbeek, J. Sjef ;
Glennie, Martin J. ;
Cragg, Mark S. .
BLOOD, 2010, 115 (25) :5191-5201
[3]   Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[4]   Potent antibody therapeutics by design [J].
Carter, PJ .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :343-357
[5]   Therapeutic antibodies for autoimmunity and inflammation [J].
Chan, Andrew C. ;
Carter, Paul J. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :301-316
[6]   Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma [J].
Cheson, Bruce D. ;
Leonard, John P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (06) :613-626
[7]   High-resolution cell surface dynamics of germinating Aspergillus fumigatus conidia [J].
Dague, Etienne ;
Alsteens, David ;
Latge, Jean-Paul ;
Dufrene, Yves F. .
BIOPHYSICAL JOURNAL, 2008, 94 (02) :656-660
[8]   Using nanotechniques to explore microbial surfaces [J].
Dufrêne, YF .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (06) :451-460
[9]  
ETZIONI R, 2003, NATURE REV CANC, V3, P1, DOI DOI 10.1038/NRC1041
[10]  
Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]